Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory Study of BK1803 in Healthy Infants
jRCT2031260370Not yet recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of BK1803 in pertussis, diphtheria, Tetanus and 3 more (4 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Primary immunogenicity endpoints – Main Cohort BK1803 group, Primary immunogenicity endpoints – Main Cohort Control group (HBs) and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BK1803
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on jRCT2031260370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260370.